Navigation Links
NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
Date:6/5/2011

tment with PLD represent a very high unmet medical need as there are currently no good treatment options available for these women.  These results demonstrate that NKTR-102 holds great therapeutic potential for women battling ovarian cancer.  We look forward to the continued late-stage development of NKTR-102." 

NKTR-102 was generally well tolerated in the subset of women with prior PLD treatment, particularly in the q21 dose schedule.  The most common Grade 3 and 4 side effects were diarrhea, hypokalemia, and nausea, with most side effects being Grade 3 in severity. [Table 3.]

NKTR-102 Phase 2 Data Presentation in Ovarian Cancer

  • The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD).
    Abstract #5047, Poster Board #15C
    General Poster Session:  Gynecologic Cancer
    Session Date and Time:  Sunday, June 5, 2011, 8:00 AM – 12:00 PM, Central Time
    Location:  Hall A

  • The NKTR-102 Phase 2 Study was an international, multicenter, open-label, randomized, two-stage study to evaluate NKTR-102 when given either on a q14d or q21d regimen in women with platinum-resistant/refractory disease to any line of platinum-based chemotherapy (platinum-free interval <6 months).  46 percent (33/71) of the women in the study had failed prior treatment with PLD.  Median lines of prior therapy for this subpopulation of women enrolled in the study were 4.  The primary endpoint of the study was objective response rate (based on RECIST and GCIG response criteria).  Secondary endpoints were safety, progression-free survival and overall survival.  TABLE 1. Patient Demographics: Prior Therapies in Subpopulation Receiving Prior Treatment with PLDNKTR-102

    145 mg/m2 q14d

    (N=16)

    NKTR-102

    145 mg/m2 q21d

    (N=17)

    Total (N=33)Prior Lines of Therapy (median)


    '/>"/>
    SOURCE Nektar Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
    2. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
    3. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
    4. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
    5. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
    6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
    7. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
    8. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
    9. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
    10. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
    11. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the patented biopharmaceutical, modernized traditional Chinese medicine ... released unaudited preliminary financial results for the first ... Year 2015 Ended September 30, 2014 Financial Highlights: ... $14.7 million in 1Q14 with gross margins improved ...
    (Date:12/24/2014)... Dec. 24, 2014  The International Trade Commission (ITC) issued ... against BMC Medical. In a notice issued on December 23, ... ResMed,s patent on its humidifier was invalid. BMC ... win". "We are very excited with the ITC,s decision in ... we have taken since the very beginning on the key ...
    (Date:12/24/2014)... and FARMINGTON, Conn. ... Inc. (NYSE MKT: PTN), a biopharmaceutical company developing ... diseases with significant unmet medical need and commercial ... a private placement of 2,050,000 shares of its ... 24,949,325 shares of its common stock.  Funds under ...
    Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
    ... 28, 2011 Life Technologies Corporation (NASDAQ: ... Imaging Station , a revolutionary platform that eliminates the ... all scientists, regardless of their technical expertise.  A high-quality ... and printed directly from the platform,s printer or downloaded ...
    ... 28, 2011  Femina Pharma Incorporated announces the issuance of ... of Certain Vaginal Ring Birth Control Devices) by the ... Commission ("ITC") denying the Merck Respondents, Motion for Summary ... The issuance of Order 24 follows the prior issuance ...
    Cached Medicine Technology:Life Technologies Makes Fluorescence Microscopy Accessible to All Scientists 2Life Technologies Makes Fluorescence Microscopy Accessible to All Scientists 3Life Technologies Makes Fluorescence Microscopy Accessible to All Scientists 4Femina Pharma Announces ALJ's Denial of Merck's Motion for Summary Determination on Domestic Industry in ITC Patent Dispute Concerning NuvaRing® 2
    (Date:12/25/2014)... 2014 Helen Harris’ RP (Retinitis Pigmentosa) ... California after an 8 year battle with breast cancer. ... evening in her home in Woodland Hills California after ... , As the founder and volunteer ... pioneered and championed many of today's greatest breakthroughs in ...
    (Date:12/25/2014)... (HealthDay News) -- Overeating is common during the holidays, but ... an expert says. "Don,t arrive at a party hungry. ... know you,ll be attending a party, but deprivation leads to ... at Northern Westchester Hospital in Mount Kisco, N.Y., said in ... during the day and even to have a snack before ...
    (Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as part of ... applications on the iOS, Android, and Windows markets. Andrew Tropeano, ... app review and shared with viewers how this is an ... saying goes, “A picture says a thousand words.” It’s true. ... single image, because each picture holds a unique and special ...
    (Date:12/24/2014)... 2014 AlignLife of Wauwatosa loves ... certain items. During the holiday season, AlignLife looks forward to ... toys," says Dr. Sara Mahalko-Leonhardt, owner of AlignLife. "It brings ... knowing that we are able to give kids toys for ... been for the generosity of our patients." , The 70 ...
    (Date:12/24/2014)... New York (PRWEB) December 24, 2014 ... mount in a mass tort litigation currently underway in ... reports. As of December 24, 2014, court documents ... proceeding on behalf of individuals who developed gynecomastia (male ... use. Data from the Court indicates that this represents ...
    Breaking Medicine News(10 mins):Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4
    ... Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) a specialty pharmaceutical ... that they anticipate reporting top-line results from their current ... of 2009. , , The Phase ... trial to evaluate the efficacy and safety of Ketotransdel, ...
    ... High Resolution Monitoring of Drug Efficacy and Safety ... Based on its recent analysis in the ... & Sullivan recognizes Singulex, Inc. with the 2009 ... Innovation for pioneering the Erenna Immunoassay System. This ...
    ... NTY ) ( www.NBTY.com ), a leading global manufacturer and marketer of nutritional supplements, today announced the ... unaudited net sales results for May 2009 by segment are as follows: , , , ... NET SALES, ... (Preliminary and Unaudited), ...
    ... -- As the slumping economy continues to ... streamlining costs and creating additional efficiencies while continuing to ... those in need for charity care or self-pay discounts. ... landscape, TransUnion announced today new enhancements to its patented ...
    ... ... seniors nationwide. , ... (Vocus) June 15, 2009 -- VaxAmerica, a program of FFF Enterprises, Inc., ... into a partnership with Emeritus Senior Living. The alliance will encourage the 26,500 seniors ...
    ... ... have developed the strongest and most effective libido/intimacy enhancement therapy called VaietTM 110/L-Arginine for ... ... to announce the release of their exclusive Viagra/Arginine Intimacy Enhancement Therapy or VAIET (named ...
    Cached Medicine News:Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 2Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 3Health News:Frost & Sullivan Recognizes Singulex for Erenna(R) Immunoassay System 2Health News:Frost & Sullivan Recognizes Singulex for Erenna(R) Immunoassay System 3Health News:Frost & Sullivan Recognizes Singulex for Erenna(R) Immunoassay System 4Health News:NBTY Announces Preliminary Unaudited Net Sales Results for May 2009 2Health News:NBTY Announces Preliminary Unaudited Net Sales Results for May 2009 3Health News:NBTY Announces Preliminary Unaudited Net Sales Results for May 2009 4Health News:TransUnion Revenue Manager(SM) Meets Healthcare Challenges Brought On By Today's Economy with New Features 2Health News:TransUnion Revenue Manager(SM) Meets Healthcare Challenges Brought On By Today's Economy with New Features 3Health News:VaxAmerica Enters Partnership with Emeritus Senior Living 2Health News:VaxAmerica Enters Partnership with Emeritus Senior Living 3Health News:After 10 Years A Stronger and More Enhanced Form of Viagra Now Available 2Health News:After 10 Years A Stronger and More Enhanced Form of Viagra Now Available 3Health News:After 10 Years A Stronger and More Enhanced Form of Viagra Now Available 4
    The rubber, whistle tip catheter with thumb valve has two side eyes to help minimize trauma....
    Soft and flexible whistle tip catheter with 2 eye configuration. "Chimney" connector with standard tapered fit and thumb control. Available in sizes 6 18 French. Packaged straight....
    ... Patient Trauma and Increase Staff Protection With Medline's ... Fr, 14 Fr, 16 Fr and 18 Fr), ... products in the U.S. We manufacture most of ... meets or exceeds our customers' expectations. We manufacture, ...
    ... Catheters are available in ... atraumatic DeLee tip with staggered ... tip. Two types of catheter ... deliver easy fingertip control with ...
    Medicine Products: